166 related articles for article (PubMed ID: 25740550)
1. Cost-effectiveness of the 21-gene breast cancer assay in Mexico.
Bargalló-Rocha JE; Lara-Medina F; Pérez-Sánchez V; Vázquez-Romo R; Villarreal-Garza C; Martínez-Said H; Shaw-Dulin RJ; Mohar-Betancourt A; Hunt B; Plun-Favreau J; Valentine WJ
Adv Ther; 2015 Mar; 32(3):239-53. PubMed ID: 25740550
[TBL] [Abstract][Full Text] [Related]
2. Using the 21-gene assay to guide adjuvant chemotherapy decision-making in early-stage breast cancer: a cost-effectiveness evaluation in the German setting.
Blohmer JU; Rezai M; Kümmel S; Kühn T; Warm M; Friedrichs K; Benkow A; Valentine WJ; Eiermann W
J Med Econ; 2013; 16(1):30-40. PubMed ID: 22966753
[TBL] [Abstract][Full Text] [Related]
3. Economic Impact of Gene Expression Profiling in Patients with Early-Stage Breast Cancer in France.
Katz G; Romano O; Foa C; Vataire AL; Chantelard JV; Hervé R; Barletta H; Durieux A; Martin JP; Salmon R
PLoS One; 2015; 10(6):e0128880. PubMed ID: 26086912
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of the 21-gene assay for guiding adjuvant chemotherapy decisions in early breast cancer.
Paulden M; Franek J; Pham B; Bedard PL; Trudeau M; Krahn M
Value Health; 2013; 16(5):729-39. PubMed ID: 23947965
[TBL] [Abstract][Full Text] [Related]
5. Economic implications of 21-gene breast cancer risk assay from the perspective of an Israeli-managed health-care organization.
Klang SH; Hammerman A; Liebermann N; Efrat N; Doberne J; Hornberger J
Value Health; 2010; 13(4):381-7. PubMed ID: 20412544
[TBL] [Abstract][Full Text] [Related]
6. Societal cost-effectiveness analysis of the 21-gene assay in estrogen-receptor-positive, lymph-node-negative early-stage breast cancer in Japan.
Yamauchi H; Nakagawa C; Yamashige S; Takei H; Yagata H; Yoshida A; Hayashi N; Hornberger J; Yu T; Chao C; Yoshizawa C; Nakamura S
BMC Health Serv Res; 2014 Sep; 14():372. PubMed ID: 25190451
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of letrozole versus tamoxifen as initial adjuvant therapy in hormone receptor-positive postmenopausal women with early-stage breast cancer.
Delea TE; Karnon J; Sofrygin O; Thomas SK; Papo NL; Barghout V
Clin Breast Cancer; 2007 Jun; 7(8):608-18. PubMed ID: 17592673
[TBL] [Abstract][Full Text] [Related]
8. Cost-utility analysis of adjuvant trastuzumab therapy for HER2-positive early-stage breast cancer in the Philippines.
Genuino AJ; Chaikledkaew U; Guerrero AM; Reungwetwattana T; Thakkinstian A
BMC Health Serv Res; 2019 Nov; 19(1):874. PubMed ID: 31752849
[TBL] [Abstract][Full Text] [Related]
9. Cost effectiveness of adjuvant trastuzumab in human epidermal growth factor receptor 2-positive breast cancer.
Liberato NL; Marchetti M; Barosi G
J Clin Oncol; 2007 Feb; 25(6):625-33. PubMed ID: 17308267
[TBL] [Abstract][Full Text] [Related]
10. Cost effectiveness of trastuzumab in the adjuvant treatment of early breast cancer: a lifetime model.
Millar JA; Millward MJ
Pharmacoeconomics; 2007; 25(5):429-42. PubMed ID: 17488140
[TBL] [Abstract][Full Text] [Related]
11. Long-term cost-effectiveness of Oncotype DX® versus current clinical practice from a Dutch cost perspective.
Kip M; Monteban H; Steuten L
J Comp Eff Res; 2015 Sep; 4(5):433-45. PubMed ID: 25872415
[TBL] [Abstract][Full Text] [Related]
12. Genomic profile of breast cancer: cost-effectiveness analysis from the Spanish National Healthcare System perspective.
Seguí MÁ; Crespo C; Cortés J; Lluch A; Brosa M; Becerra V; Chiavenna SM; Gracia A
Expert Rev Pharmacoecon Outcomes Res; 2014 Dec; 14(6):889-99. PubMed ID: 25213317
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of extended adjuvant letrozole therapy after 5 years of adjuvant tamoxifen therapy in postmenopausal women with early-stage breast cancer.
Delea TE; Karnon J; Smith RE; Johnston SR; Brandman J; Sung JC; Gross PE
Am J Manag Care; 2006 Jul; 12(7):374-86. PubMed ID: 16834524
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of letrozole versus tamoxifen as initial adjuvant therapy in postmenopausal women with hormone-receptor positive early breast cancer from a Canadian perspective.
Delea TE; El-Ouagari K; Karnon J; Sofrygin O
Breast Cancer Res Treat; 2008 Apr; 108(3):375-87. PubMed ID: 17653859
[TBL] [Abstract][Full Text] [Related]
15. Economic evaluation of genomic test-directed chemotherapy for early-stage lymph node-positive breast cancer.
Hall PS; McCabe C; Stein RC; Cameron D
J Natl Cancer Inst; 2012 Jan; 104(1):56-66. PubMed ID: 22138097
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness analysis of trastuzumab in the adjuvant setting for treatment of HER2-positive breast cancer.
Garrison LP; Lubeck D; Lalla D; Paton V; Dueck A; Perez EA
Cancer; 2007 Aug; 110(3):489-98. PubMed ID: 17592827
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness analysis of anastrozole versus tamoxifen as primary adjuvant therapy for postmenopausal women with early breast cancer: a US healthcare system perspective. The 5-year completed treatment analysis of the ATAC ('Arimidex', Tamoxifen Alone or in Combination) trial.
Locker GY; Mansel R; Cella D; Dobrez D; Sorensen S; Gandhi SK;
Breast Cancer Res Treat; 2007 Dec; 106(2):229-38. PubMed ID: 17245540
[TBL] [Abstract][Full Text] [Related]
18. Cost effectiveness of a 21-gene recurrence score assay versus Canadian clinical practice in post-menopausal women with early-stage estrogen or progesterone-receptor-positive, axillary lymph-node positive breast cancer.
Hannouf MB; Xie B; Brackstone M; Zaric GS
Pharmacoeconomics; 2014 Feb; 32(2):135-47. PubMed ID: 24288208
[TBL] [Abstract][Full Text] [Related]
19. A cost-consequence model of using the 21-gene assay to identify patients with early-stage node-positive breast cancer who benefit from adjuvant chemotherapy in the Netherlands.
Simons MJHG; Machielsen PM; Spoorendonk JA; Ignacio T; Drost PB; Jacobs T; de Jongh FE
J Med Econ; 2024; 27(1):445-454. PubMed ID: 38436289
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness analysis of the Oncotype DX Breast Recurrence Score test in node-positive early breast cancer.
Berdunov V; Millen S; Paramore A; Hall P; Perren T; Brown R; Griffin J; Reynia S; Fryer N; Longworth L
J Med Econ; 2022; 25(1):591-604. PubMed ID: 35416089
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]